BLADURIL Film-coated tablet Ref.[50643] Active ingredients: Flavoxate

Source: Health Products Regulatory Authority (ZA)  Revision Year: 2022  Publisher: Adcock Ingram Limited, 1 New Road, Erand Gardens, Midrand, 1685, South Africa 0860 ADCOCK (232625)

4.1. Therapeutic indications

BLADURIL is indicated for its antispasmodic action in urological disorders.

4.2. Posology and method of administration

Posology

Adults

One tablet three times a day (600 mg flavoxate hydrochloride) for as long as required.

Paediatric population

The safety and efficacy of BLADURIL in children aged < 12 years have not been established (see section 4.3).

Method of administration

BLADURIL is for oral use.

4.9. Overdose

The most likely symptoms of overdose are blurred vision, dry mouth, drowsiness, and diarrhoea or constipation. Treatment of overdosage is symptomatic and supportive.

6.3. Shelf life

36 months.

6.4. Special precautions for storage

Do not store above 30°C.

Protect from moisture and light.

Keep the blister strips in the outer carton.

6.5. Nature and contents of container

Cartons of 15 tablets: Each carton contains 1 blister strip containing 15 tablets.

Cartons of 90 tablets: Each carton contains 6 blister strips containing 15 tablets per blister strip.

Not all pack sizes may be marketed.

6.6. Special precautions for disposal and other handling

Any unused product or waste material should be disposed of in accordance with local requirements.

No special requirements.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.